Paradigm Biopharma Draws US$3 Million to Support Phase 3 Osteoarthritis Trial

Fourth Tranche Drawdown Strengthens Trial Funding

Paradigm Biopharmaceuticals Ltd. (ASX:PAR) has completed the drawdown of Tranche 4 under its US$27 million convertible note facility with Obsidian Global Partners, securing US$3 million (approximately A$4.6 million). This latest funding injection comes as the company advances its global Phase 3 clinical trial (PARA_OA_012) assessing injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis, following the successful enrolment of 538 participants.

Clinical Trial Progress and Operational Milestones

Since the previous tranche, Paradigm has reached several key operational milestones, including completing participant enrolment across a broad network of clinical sites spanning the United States, Australia, Hong Kong, and Moldova. The trial continues with dosing and follow-up activities as it moves toward its planned interim analysis, which is a critical juncture for assessing efficacy and safety data.

The Tranche 4 funds are earmarked to support ongoing patient treatment, follow-up assessments, database management, regulatory compliance, and clinical operations. This financial boost is timed to ensure smooth progression toward the interim analysis and the subsequent top-line primary endpoint readout, both pivotal for the company’s development timeline.

Financial Flexibility Maintained for Upcoming Milestones

Following this drawdown, approximately US$7 million (around A$10.7 million) remains available under the convertible note facility, offering Paradigm continued financial flexibility to execute the remainder of the Phase 3 trial and prepare for commercial readiness activities. The company emphasises disciplined capital management, aligning expenditure closely with operational progress to maintain funding through key milestones including the interim analysis and final data readout.